Amarin presents new REDUCE-IT analyses

Amarin (AMRN) highlighted three sub-analyses from the REDUCE-IT trial describing the impact of VASCEPA/VAZKEPA administration on cardiovascular disease risk associated with Cardiovascular-Kidney-Metabolic syndrome, major adverse cardiovascular events stratified by baseline apolipoprotein B and fasting triglyceride rich lipoprotein cholesterol levels, and on hospitalizations. All three post hoc analyses showed significant reductions in cardiovascular risk and outcomes in the populations studied. The data was presented at the European Society of Cardiology Congress 2025 in Madrid, Spain. “The REDUCE-IT data continue to yield important insights into the clinical utility of VASCEPA/VAZKEPA and how icosapent ethyl can reduce cardiovascular risk across diverse patient populations. These new analyses reinforce the robustness of the original findings and highlight the potential of icosapent ethyl to address complex conditions like cardiovascular-kidney-metabolic syndrome and lipid-driven risk. The consistency of benefit observed across multiple high-risk subgroups supports its integration into contemporary treatment strategies as a complementary therapy aimed at improving patient outcomes,” said Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Fuster Heart Hospital.